Skip to content

Gyre Therapeutics

Primary Menu

About
Science
Investors
Contact

Hemophila B Gene Therapy in Mice using a Novel Chimeric AAV Capsid Combined with a Potency Enhanced FIX Variant

Post navigation

Previous: Phase 2b Trial to Evaluate the Safety & Factor IX Levels Resulting from a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog Alfa in Haemophilia B

Next: CB 2679d-GT – A Novel Human Factor IX Variant Shows Enhanced Activity After Delivery Into Hemophilic Mice Using an AAV Capsid With High Liver Transduction

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

About
- Management Team
- Board of Directors
Science
Investors
Contact

Gyre Therapeutics

Gyre Therapeutics, Inc.
| 12770 High Bluff Drive, Suite 150,
San Diego, CA 92130

© Gyre Therapeutics, Inc. All rights reserved.
Terms of Use Privacy Policy

X

Previous

Next